Radiotherapy for Oligometastatic Lung Cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
2010, Chemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancer, Cochrane Database Syst Rev, 5, CD007309, 10.1002/14651858.CD007309.pub2
Reck, 2016, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N Engl J Med, 375, 1823, 10.1056/NEJMoa1606774
Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer, N Engl J Med, 373, 1627, 10.1056/NEJMoa1507643
Zhou, 2011, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study, Lancet Oncol, 12, 735, 10.1016/S1470-2045(11)70184-X
Chang, 2015, Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials, Lancet Oncol, 16, 630, 10.1016/S1470-2045(15)70168-3
Timmerman, 2010, Stereotactic body radiation therapy for inoperable early stage lung cancer, JAMA, 303, 1070, 10.1001/jama.2010.261
Milano, 2012, Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study, Int J Radiat Oncol Biol Phys, 83, 878, 10.1016/j.ijrobp.2011.08.036
Nyman, 2016, SPACE – a randomized study of SBRT vs conventional fractionated radiotherapy in medically inoperable stage I NSCLC, Radiother Oncol, 121, 1, 10.1016/j.radonc.2016.08.015
Fuks, 2005, Engaging the vascular component of the tumor response, Cancer Cell, 8, 89, 10.1016/j.ccr.2005.07.014
Park, 2012, Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS), Radiat Res, 177, 311, 10.1667/RR2773.1
Lewis, 2015, Definitive stereotactic body radiotherapy (SBRT) for extracranial oligometastases: an international survey of >1000 radiation oncologists, Am J Clin Oncol, 40, 418, 10.1097/COC.0000000000000169
Fisher, 1999, From Halsted to prevention and beyond: advances in the management of breast cancer during the twentieth century, Eur J Cancer, 35, 1963, 10.1016/S0959-8049(99)00217-8
Halsted, 1907, I. The results of radical operations for the cure of carcinoma of the breast, Ann Surg, 46, 1, 10.1097/00000658-190707000-00001
Mehta, 2004, Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment, Int J Oncol, 25, 1677, 10.3892/ijo.25.6.1677
Rusthoven, 2009, Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis, Acta Oncol, 48, 578, 10.1080/02841860802662722
Kanas, 2012, Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors, Clin Epidemiol, 4, 283, 10.2147/CLEP.S34285
Predina, 2011, Improved survival after pulmonary metastasectomy for soft tissue sarcoma, J Thorac Oncol, 6, 913, 10.1097/JTO.0b013e3182106f5c
Salama, 2014, The role of surgery and ablative radiotherapy in oligometastatic breast cancer, Semin Oncol, 41, 790, 10.1053/j.seminoncol.2014.09.016
Bergsma, 2015, The evolving role of radiotherapy in treatment of oligometastatic NSCLC, Expert Rev Anticancer Ther, 15, 1459, 10.1586/14737140.2015.1105745
Ashworth, 2014, An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer, Clin Lung Cancer, 15, 346, 10.1016/j.cllc.2014.04.003
Parikh, 2014, Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer, Int J Radiat Oncol Biol Phys, 89, 880, 10.1016/j.ijrobp.2014.04.007
Yano, 2013, Local treatment of oligometastatic recurrence in patients with resected non-small cell lung cancer, Lung Cancer, 82, 431, 10.1016/j.lungcan.2013.08.006
Torok, 2013, Patterns of distant metastases in surgically managed early stage non-small cell lung cancer, 2013
Albain, 1991, Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience, J Clin Oncol, 9, 1618, 10.1200/JCO.1991.9.9.1618
Cheruvu, 2011, Comparison of outcomes in patients with stage III versus limited stage IV non-small cell lung cancer, Radiat Oncol, 6, 80, 10.1186/1748-717X-6-80
Goldstraw, 2016, The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer, J Thorac Oncol, 11, 39, 10.1016/j.jtho.2015.09.009
Zakaria, 2014, The role of magnetic resonance imaging in the management of brain metastases: diagnosis to prognosis, Cancer Imaging, 14, 8, 10.1186/1470-7330-14-8
Li, 2013, Meta-analysis: accuracy of 18FDG PET-CT for distant metastasis staging in lung cancer patients, Surg Oncol, 22, 151, 10.1016/j.suronc.2013.04.001
Tonnies, 2016, Impact of preoperative 18F-FDG PET/CT on survival of resected mono-metastatic non-small cell lung cancer, Lung Cancer, 93, 28, 10.1016/j.lungcan.2015.12.008
Dinan, 2012, Stage migration, selection bias, and survival associated with the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998–2003, J Clin Oncol, 30, 2725, 10.1200/JCO.2011.40.4392
Weber, 2003, [PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer], Nuklearmedizin, 42, 135, 10.1055/s-0038-1625183
Palma, 2014, The oligometastatic state – separating truth from wishful thinking, Nat Rev Clin Oncol, 11, 549, 10.1038/nrclinonc.2014.96
Patel, 2012, A call for the aggressive treatment of oligometastatic and oligo-recurrent non-small cell lung cancer, Pulm Med, 2012, 480961, 10.1155/2012/480961
Camidge, 2014, Acquired resistance to TKIs in solid tumours: learning from lung cancer, Nat Rev Clin Oncol, 11, 473, 10.1038/nrclinonc.2014.104
Fleckenstein, 2016, Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer, BMC Cancer, 16, 348, 10.1186/s12885-016-2379-x
Oh, 2009, Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases, Cancer, 115, 2930, 10.1002/cncr.24333
Pfannschmidt, 2010, Surgical treatment of oligometastatic non-small cell lung cancer, Lung Cancer, 69, 251, 10.1016/j.lungcan.2010.05.003
Collaud, 2012, Survival of patients treated surgically for synchronous single-organ metastatic NSCLC and advanced pathologic TN stage, Lung Cancer, 78, 234, 10.1016/j.lungcan.2012.09.011
Congedo, 2012, Surgery for oligometastatic non-small cell lung cancer: long-term results from a single center experience, J Thorac Cardiovasc Surg, 144, 444, 10.1016/j.jtcvs.2012.05.051
Patchell, 1990, A randomized trial of surgery in the treatment of single metastases to the brain, N Engl J Med, 322, 494, 10.1056/NEJM199002223220802
Di Lascio, 2014, Oligometastatic breast cancer: a shift from palliative to potentially curative treatment?, Breast Care (Basel), 9, 7, 10.1159/000358750
Leksell, 1951, The stereotaxic method and radiosurgery of the brain, Acta Chir Scand, 102, 316
Sahgal, 2015, Stereotactic radiosurgery alone for brain metastases, Lancet Oncol, 16, 249, 10.1016/S1470-2045(14)71106-4
Onishi, 2007, Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study, J Thorac Oncol, 2, S94, 10.1097/JTO.0b013e318074de34
Gomez, 2016, Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study, Lancet Oncol, 17, 1672, 10.1016/S1470-2045(16)30532-0
Iyengar, 2014, Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer, J Clin Oncol, 32, 3824, 10.1200/JCO.2014.56.7412
Collen, 2014, Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic nonsmall-cell lung cancer patients, Ann Oncol, 25, 1954, 10.1093/annonc/mdu370
De Ruysscher, 2012, Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450), J Thorac Oncol, 7, 1547, 10.1097/JTO.0b013e318262caf6
Griffioen, 2013, Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors, Lung Cancer, 82, 95, 10.1016/j.lungcan.2013.07.023
Weickhardt, 2012, Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer, J Thorac Oncol, 7, 1807, 10.1097/JTO.0b013e3182745948
Hasselle, 2012, Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer, J Thorac Oncol, 7, 376, 10.1097/JTO.0b013e31824166a5
Jabbour, 2011, A novel paradigm in the treatment of oligometastatic non-small cell lung cancer, J Thorac Dis, 3, 4, 10.3978/j.issn.2072-1439.2010.12.09
Yano, 2010, Prognostic impact of local treatment against postoperative oligometastases in non-small cell lung cancer, J Surg Oncol, 102, 852, 10.1002/jso.21750
Khan, 2006, Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC), Radiother Oncol, 81, 163, 10.1016/j.radonc.2006.09.006
Schellinger, 1999, Diagnostic accuracy of MRI compared to CCT in patients with brain metastases, J Neurooncol, 44, 275, 10.1023/A:1006308808769
Mehta, 2017, The changing role of whole-brain radiotherapy: demise or time for selective usage?, JAMA Oncol, 3, 1021, 10.1001/jamaoncol.2016.5414
Sperduto, 2012, Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases, J Clin Oncol, 30, 419, 10.1200/JCO.2011.38.0527
Andrews, 2004, Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial, Lancet, 363, 1665, 10.1016/S0140-6736(04)16250-8
Brown, 2015, NCCTG N0574 (Alliance): a phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases, J Clin Oncol, 33, lba4, 10.1200/jco.2015.33.15_suppl.lba4
Brown, 2016, Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial, JAMA, 316, 401, 10.1001/jama.2016.9839
Mahajan, 2017, Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial, Lancet Oncol, 18, 1040, 10.1016/S1470-2045(17)30414-X
Brown, 2017, Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial, Lancet Oncol, 18, 1049, 10.1016/S1470-2045(17)30441-2
Minniti, 2016, Single-fraction versus multifraction (3 x 9 Gy) stereotactic radiosurgery for large (>2 cm) brain metastases: a comparative analysis of local control and risk of radiation-induced brain necrosis, Int J Radiat Oncol Biol Phys, 95, 1142, 10.1016/j.ijrobp.2016.03.013
Yamamoto, 2014, Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study, Lancet Oncol, 15, 387, 10.1016/S1470-2045(14)70061-0
Eberhardt, 2015, The IASLC lung cancer staging project: proposals for the revision of the M descriptors in the forthcoming eighth edition of the TNM classification of lung cancer, J Thorac Oncol, 10, 1515, 10.1097/JTO.0000000000000673
Rusthoven, 2009, Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases, J Clin Oncol, 27, 1579, 10.1200/JCO.2008.19.6386
De Rose, 2016, Clinical outcome of stereotactic ablative body radiotherapy for lung metastatic lesions in non-small cell lung cancer oligometastatic patients, Clin Oncol (R Coll Radiol), 28, 13, 10.1016/j.clon.2015.08.011
Patel, 2015, Treatment considerations for synchronous primary NSCLC and oligometastatic disease, Treatment of High-Risk Early Stage Lung Cancer
Ehrbar, 2016, Respiratory motion-management in stereotactic body radiation therapy for lung cancer – a dosimetric comparison in an anthropomorphic lung phantom (LuCa), Radiother Oncol, 121, 328, 10.1016/j.radonc.2016.10.011
Almaghrabi, 2012, Stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical review, Radiat Oncol, 7, 126, 10.1186/1748-717X-7-126
Chong, 2006, Integrated PET-CT for the characterization of adrenal gland lesions in cancer patients: diagnostic efficacy and interpretation pitfalls, Radiographics, 26, 1811, 10.1148/rg.266065057
Porte, 2001, Resection of adrenal metastases from non-small cell lung cancer: a multicenter study, Ann Thorac Surg, 71, 981, 10.1016/S0003-4975(00)02509-1
Soffen, 1990, Palliative radiotherapy for symptomatic adrenal metastases, Cancer, 65, 1318, 10.1002/1097-0142(19900315)65:6<1318::AID-CNCR2820650611>3.0.CO;2-H
Chance, 2016, Stereotactic ablative radiotherapy for adrenal gland metastases: factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity, Pract Radiat Oncol, 7, e195, 10.1016/j.prro.2016.09.005
Casamassima, 2012, Stereotactic radiotherapy for adrenal gland metastases: University of Florence experience, Int J Radiat Oncol Biol Phys, 82, 919, 10.1016/j.ijrobp.2010.11.060
Ippolito, 2015, SBRT: a viable option for treating adrenal gland metastases, Rep Pract Oncol Radiother, 20, 484, 10.1016/j.rpor.2015.05.009
Kagohashi, 2003, Liver metastasis at the time of initial diagnosis of lung cancer, Med Oncol, 20, 25, 10.1385/MO:20:1:25
Rusthoven, 2009, Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases, J Clin Oncol, 27, 1572, 10.1200/JCO.2008.19.6329
Goodman, 2016, Long-term safety and efficacy of stereotactic body radiation therapy for hepatic oligometastases, Pract Radiat Oncol, 6, 86, 10.1016/j.prro.2015.10.011
Ahmed, 2016, Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes after stereotactic body radiation therapy, Int J Radiat Oncol Biol Phys, 95, 1399, 10.1016/j.ijrobp.2016.03.050
Wu, 2008, The impact of respiratory motion and treatment technique on stereotactic body radiation therapy for liver cancer, Med Phys, 35, 1440, 10.1118/1.2839095
Agarwala, 2005, Long-term survival in a patient with stage IV non-small-cell lung carcinoma after bone metastasectomy, Clin Lung Cancer, 6, 367, 10.3816/CLC.2005.n.017
Ambrogi, 2001, Skin metastases in lung cancer: analysis of a 10-year experience, Oncol Rep, 8, 57, 10.3892/or.8.1.57
Gerszten, 2007, Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution, Spine (Phila Pa 1976), 32, 193, 10.1097/01.brs.0000251863.76595.a2
Owen, 2014, Outcomes and toxicities of stereotactic body radiation therapy for non-spine bone oligometastases, Pract Radiat Oncol, 4, e143, 10.1016/j.prro.2013.05.006
Flanigan, 2004, Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis, J Urol, 171, 1071, 10.1097/01.ju.0000110610.61545.ae
Perez, 1987, Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group, Cancer, 59, 1874, 10.1002/1097-0142(19870601)59:11<1874::AID-CNCR2820591106>3.0.CO;2-Z
Koshy, 2015, Comparative effectiveness of aggressive thoracic radiation therapy and concurrent chemoradiation therapy in metastatic lung cancer, Pract Radiat Oncol, 5, 374, 10.1016/j.prro.2015.07.009
Stevens, 2015, Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer, Cochrane Database Syst Rev, 1, CD002143, 10.1002/14651858.CD002143.pub4
Li, 2017, Should aggressive thoracic therapy be performed in patients with synchronous oligometastatic non-small cell lung cancer? A meta-analysis, J Thorac Dis, 9, 310, 10.21037/jtd.2017.02.21
Li, 2015, A phase II prospective study of definitive thoracic concurrent chemoradiation followed by consolidation chemotherapy for oligometastatic non-small cell lung cancer, J Clin Oncol, 33, e19008, 10.1200/jco.2015.33.15_suppl.e19008
Gray, 2014, Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival, Lung Cancer, 85, 239, 10.1016/j.lungcan.2014.06.001
Xanthopoulos, 2015, Definitive dose thoracic radiation therapy in oligometastatic non-small cell lung cancer: a hypothesis-generating study, Pract Radiat Oncol, 5, e355, 10.1016/j.prro.2014.11.006
Hotta, 2004, Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials, J Clin Oncol, 22, 3860, 10.1200/JCO.2004.02.109
Cheung, 2016, Stereotactic body radiotherapy for oligoprogressive cancer, Br J Radiol, 89, 20160251, 10.1259/bjr.20160251
Golden, 2015, Local radiotherapy and granulocyte-macrophage colony-stimulatingfactor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial, Lancet Oncol, 16, 795, 10.1016/S1470-2045(15)00054-6
Shaverdian, 2017, Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial, Lancet Oncol, 18, 895, 10.1016/S1470-2045(17)30380-7
Kroeze, 2017, Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: a systematic review, Cancer Treat Rev, 53, 25, 10.1016/j.ctrv.2016.11.013
Bang, 2017, Multicenter evaluation of the tolerability of combined treatment with PD-1 and CTLA-4 immune checkpoint inhibitors and palliative radiation therapy, Int J Radiat Oncol Biol Phys, 98, 344, 10.1016/j.ijrobp.2017.02.003
Tang, 2014, Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes, Int J Radiat Oncol Biol Phys, 89, 1084, 10.1016/j.ijrobp.2014.04.025
Clarke, 2015, Surrogate clinical endpoints to predict overall survival in non-small cell lung cancer trials – are we in a new era?, Transl Lung Cancer Res, 4, 804, 10.3978/j.issn.2218-6751.2015.05.03
Salama, 2012, Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease, Cancer, 118, 2962, 10.1002/cncr.26611
Wong, 2016, Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT), Cancer, 122, 2242, 10.1002/cncr.30058
Eke, 2016, Comprehensive molecular tumor profiling in radiation oncology: how it could be used for precision medicine, Cancer Lett, 382, 118, 10.1016/j.canlet.2016.01.041
Daly, 2015, Clinical trials integrating immunotherapy and radiation for non-small-cell lung cancer, J Thorac Oncol, 10, 1685, 10.1097/JTO.0000000000000686
Aggarwal, 2016, Palliative radiotherapy: evolving role and policy challenges, J Cancer Policy, 10, 21, 10.1016/j.jcpo.2016.05.003